"I think our preliminary assessment indicates that vaccines will require a dedicated manufacturing facility and it cannot be produced in a facility where we are making multiple other products," Sun Pharmaceutical Industries Managing Director Dilip Shanghvi said in a call with analysts.
Mumbai (Maharashtra) [India], May 27 (ANI): Sun Pharmaceutical Industries on Thursday posted 124 per cent increase in consolidated net profit at Rs 894 crore for the January to March quarter as compared to Rs 400 crore in the year-ago period.